PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Serial Lamotrigine Levels Fail to Predict Pregnancy Seizures

lamotrigineantiseizure medicationsepilepsypregnancytherapeutic drug monitoringseizure predictionEMPiREjoint modellingpharmacokinetics Neurology / Neuropharmacology

Background Information

Baseline dosing outshines serum levels for predicting seizures in pregnancy.

Predicting seizure risk in pregnant women with epilepsy is crucial for managing treatment and maintaining safety. Serial measurement of lamotrigine concentrations did not improve seizure prediction, with baseline lamotrigine dose being a better predictor (HR 1.005, 95% CI 1.003 to 1.007). Routine serial monitoring of lamotrigine levels in pregnancy may not be necessary for seizure prediction. Focus on baseline dosing may be more effective. Baseline lamotrigine dose predicts seizure risk better than serum concentration monitoring in pregnancy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Allotey J, Junaid F, Peréz T, Rolle V, Pardo MDC, Zamora J, Thangaratinam S

Citation: Allotey J, Junaid F, Peréz T, et al. Lamotrigine serum concentrations as longitudinal biomarkers for seizure risk prediction in pregnant women with epilepsy: a secondary analysis of the EMPiRE study. BMJ neurology open. 2026;8(1):e001547. doi:10.1136/bmjno-2026-001547

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →